Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • Jan. 24, 2012, 12:52 PM
    Dendreon (DNDN +6.4%) catches a bid on more rumors (previous) that the firm is in the sights of Amgen (AMGN +0.4%) as an acquisition.
    | Jan. 24, 2012, 12:52 PM | Comment!
  • Jan. 23, 2012, 3:48 PM
    Part of J.P. Morgan's biotech (IBB -0.5%) cuts after the sector's recent run (I, II) include a move to Neutral from Overweight on Allos Therapeutics (ALTH +1.2%), noting that EU approval of its lymphoma drug looks at risk following last week's negative opinion from a European panel. Morgan's other calls lowered AMAG -6%, ACOR -0.5%, AMGN -2.5% and VPHM -2.4%.
    | Jan. 23, 2012, 3:48 PM | Comment!
  • Jan. 23, 2012, 9:53 AM
    Shares of AMAG Pharmaceuticals (AMG -4.4%) move lower after the firm takes on a downgrade from JPMorgan to Underweight. The ratings move on AMAG is part of a larger sector call that includes VPHM, ACOR, AMGN, and ALTH all getting slashed on valuation.
    | Jan. 23, 2012, 9:53 AM | Comment!
  • Jan. 6, 2012, 10:25 AM
    Lagging biotechs Amgen (AMGN -0.2%) and Celgene (CELG -2%) may dive into deal-making this year in seeking to return to the industry’s high-growth roots, Bloomberg speculates. Investors in the space have rewarded strategic acquisitions and companies that continue to develop innovative therapies, rather than dividend-paying low-growth stocks.
    | Jan. 6, 2012, 10:25 AM | Comment!
  • Dec. 29, 2011, 1:31 PM
    BofA weighs in on Amgen (AMGN +1.1%) after digesting recent events related to the firm including its planned buyback of $5B worth of stock. Analysts cite prescription sales trends and a favorable dollar/euro climate as drivers, as they slot in 2012 EPS at $6.13 vs. the Street's $5.82.
    | Dec. 29, 2011, 1:31 PM | Comment!
  • Dec. 19, 2011, 4:36 PM
    Amgen (AMGN) and Watson Pharmaceuticals (WPI) will collaborate to develop and market several oncology antibody biosimilar medicines. Under the terms of the agreement, Amgen will assume primary responsibility for development and manufacturing, while Watson will contribute up to $400M in co-development costs, provide development support and will share product development risks.
    | Dec. 19, 2011, 4:36 PM | Comment!
  • Dec. 16, 2011, 7:07 AM
    Goldman Sachs upgrades Amgen (AMGN) to Neutral from Sell on the heels of the biotech concern's change in management. Analysts with the firm have been calling for a "new strategic direction" for AMGN for quite a while.
    | Dec. 16, 2011, 7:07 AM | Comment!
  • Dec. 16, 2011, 4:52 AM
    Amgen (AMGN) CEO Kevin Sharer will retire in May and be replaced by company President and COO Robert Bradway. RBC Capital analyst Michael Yee says the biotech's new CEO will need to "reinvigorate a focus of innovation for new products and a focus on cutting expenses." Are both those possible? (PR)
    | Dec. 16, 2011, 4:52 AM | 1 Comment
  • Dec. 15, 2011, 4:09 PM
    Amgen (AMGN) rises slightly after boosting its quarterly dividend by $0.08/share, to $0.36/share. Following the hike, Amgen sports an annual yield of 2.5%.
    | Dec. 15, 2011, 4:09 PM | Comment!
  • Dec. 13, 2011, 7:01 PM
    Amgen (AMGN) says data from Phase 3 tests for its immune thrombocytopenia drug Nplate showed postitive results, and was presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology over the weekend in San Diego. 
    | Dec. 13, 2011, 7:01 PM | Comment!
  • Dec. 8, 2011, 12:49 PM
    Biotech firm Amgen (AMGN) expects to repurchase almost $5B worth of stock - or around 83.3M shares at $60 a pop - following a Dutch auction. The buyback represents about half of a $10B program. Shares +0.4%. (PR)
    | Dec. 8, 2011, 12:49 PM | Comment!
  • Dec. 8, 2011, 11:33 AM
    Affymax (AFFY +41.3%) skyrockets following yesterday's recommendation by an FDA advisory panel for its peginesatide treatment of anemia in dialysis patients. Cowen believes the drug can capture $250M in U.S. sales by 2016, and Raymond James suspects AFFY can take market share if it prices its drug lower than Amgen's (AMGN +1%) Epogen.
    | Dec. 8, 2011, 11:33 AM | Comment!
  • Dec. 7, 2011, 6:14 PM
    Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon.
    | Dec. 7, 2011, 6:14 PM | 1 Comment
  • Dec. 6, 2011, 1:16 PM
    Amgen (AMGN -0.2%) announces that it has struck an agreement with the FDA to modify its Nplate treatment designed to treat an immune system disorder that attacks blood elements. "The FDA has now concluded that enrollment in a restricted distribution program is no longer necessary to prescribe or receive Nplate."
    | Dec. 6, 2011, 1:16 PM | Comment!
  • Nov. 18, 2011, 3:34 PM
    Dialysis clinic operator DaVita (DVA +3.1%) signs a new, seven-year agreement to receive Amgen's (AMGN -0.5%) anti-anemia drug Epogen. In an SEC filing, Amgen discloses that the Epogen it supplies will meet at least 90% of DaVita's requirements for erythropoiesis stimulating agents in clinics in the U.S. and Puerto Rico.
    | Nov. 18, 2011, 3:34 PM | Comment!
  • Nov. 14, 2011, 3:50 PM
    An experimental Amgen (AMGN -0.8%) drug shows it has the potential to lower bad cholesterol via an injected monoclonal antibody designed to inhibit the action of a protein called PCSK9, which is involved with the regulation of LDL (bad cholesterol). Sanofi (SNY) and Regeneron (REGN) are believed to have progressed the most in developing products that target PCSK9.
    | Nov. 14, 2011, 3:50 PM | Comment!
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States